

In re Generic Pharmaceuticals Pricing Antitrust Litigation
Settlement Administrator
PO Box 2750
Portland, OR 97208-2750

Court-Approved Legal Notice

*In re Generic Pharmaceuticals Pricing
Antitrust Litigation,*

Case No. 16-md-2724
United States District Court for the Eastern
District of Pennsylvania

**If you are a dispenser of drugs in
the U.S. that purchased one or more
“Drugs at Issue” from January 1, 2010,
through March 5, 2024, you may be
entitled to benefits from a settlement.**

*A Court has authorized this notice.
This is **not** a solicitation from a lawyer.*

www.GenericPharmaceuticalsAntitrust.com

1-877-644-0182

A \$5.5 million Settlement has been reached in a class action antitrust lawsuit between Indirect Reseller Plaintiffs and Defendant Apotex Corp. (“Apotex”). The Settlement only applies to Apotex, with the lawsuit continuing against other Defendants. The lawsuit is called *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, Case No. 16-md-2724 (E.D. Penn.). The Settlement will resolve claims that Apotex participated in one or more unlawful conspiracies to raise, fix, maintain, and/or stabilize prices, rig bids, and allocate markets and customers for “Drugs at Issue” in violation of Section 1 of the Sherman Act and various state antitrust, unfair competition, unjust enrichment, and consumer protection laws. The “Drugs at Issue” are listed at www.GenericPharmaceuticalsAntitrust.com.

Who is Included? Records show you are a member of the Settlement Class defined as: All dispensers of drugs (including Clinics, Hospitals and Independent Pharmacies) in the United States and its territories that purchased one or more Drugs at Issue from January 1, 2010 through March 5, 2024, including (a) those that purchased directly from distributor AmerisourceBergen Drug Corporation, Cardinal Health, Inc., Red Oak Sourcing, LLC, The Harvard Drug Group, LLC, HD Smith LLC, McKesson Corporation, Morris & Dickson Co., LLC or Walgreens Boot Alliance, Inc. or their subsidiaries; and (b) those that purchased indirectly from any Defendant in the MDL.

What does the Settlement Provide? The Settlement has been approved. Apotex is required to pay \$5,260,842 to resolve all Settlement Class Members’ legal claims against Apotex for the Released Claims (as defined in the Settlement Agreement). In addition to this monetary benefit, Apotex has also agreed to provide specified cooperation in the Indirect Reseller Plaintiffs’ continued prosecution of the lawsuit.

To receive settlement benefits, you must submit a timely and valid Claim Form online or by mail postmarked by **August 28, 2025**. Claims Forms can be submitted online at www.GenericPharmaceuticalsAntitrust.com or mailed to the Settlement Administrator at the address below. Claims Forms are also available on the Settlement Website at www.GenericPharmaceuticalsAntitrust.com, by calling 1-877-644-0182 or by writing to the address below:

In re Generic Pharmaceuticals Pricing Antitrust Litigation
Settlement Administrator
PO Box 2750
Portland, OR 97208-2750

This notice is a summary. Learn more about the Settlement at www.GenericPharmaceuticalsAntitrust.com or by calling toll free 1-877-644-0182.